TG Therapeutics (TGTX) News Today $35.14 -0.10 (-0.28%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$35.38 +0.24 (+0.68%) As of 05/28/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TGTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period TG Therapeutics: Estimates Could Soon Be Raised AgainMay 28 at 7:01 AM | seekingalpha.comBank of America Corp DE Has $6.95 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)Bank of America Corp DE cut its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 86.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 230,939 shares of the biopharmaceutical compMay 28 at 3:16 AM | marketbeat.comTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual MeetingMay 27 at 7:30 AM | globenewswire.comConnecticut Wealth Management LLC Sells 13,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)Connecticut Wealth Management LLC lessened its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 46.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,782 shares of the biopharmaceMay 25, 2025 | marketbeat.comTwo Sigma Investments LP Trims Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Two Sigma Investments LP trimmed its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 43.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 606,208 shares of the bioMay 25, 2025 | marketbeat.comProShare Advisors LLC Acquires 12,951 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)ProShare Advisors LLC increased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 44.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,955 shares of the biopharmaceuMay 25, 2025 | marketbeat.comCaptrust Financial Advisors Sells 22,765 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)Captrust Financial Advisors trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 75.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,562 shares of the biopharmaceutical company's stock after sellingMay 24, 2025 | marketbeat.comCastleark Management LLC Increases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)Castleark Management LLC lifted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 25.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 211,370 shares of the biopharmaceutical company's stocMay 23, 2025 | marketbeat.comDeutsche Bank AG Has $4.43 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Deutsche Bank AG lifted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 40.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 147,020 shares of the biopharmaceutical company's stock after acquiring an additional 4May 22, 2025 | marketbeat.comSoleus Capital Management L.P. Has $80.71 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Soleus Capital Management L.P. raised its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 5.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,681,242 sharesMay 21, 2025 | marketbeat.comWexford Capital LP Invests $421,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)Wexford Capital LP acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 14,000 shares of the biopharmaceutical company's stock, valued at approximaMay 21, 2025 | marketbeat.comNuveen Asset Management LLC Has $54.15 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)Nuveen Asset Management LLC lowered its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 11.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,798,989 shares of the biopharmaceutical company'sMay 21, 2025 | marketbeat.comBalyasny Asset Management L.P. Invests $274,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)Balyasny Asset Management L.P. acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 9,100 shares of the bMay 20, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by BNP Paribas Financial MarketsBNP Paribas Financial Markets trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 49.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,710 shares of the biopharmaceutMay 20, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of "Moderate Buy" by BrokeragesTG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy ratinMay 20, 2025 | marketbeat.comRafferty Asset Management LLC Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)Rafferty Asset Management LLC reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 2.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 331,412 shares of the biopharmaceuticaMay 19, 2025 | marketbeat.comGotham Asset Management LLC Sells 64,333 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)Gotham Asset Management LLC reduced its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 55.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,949 sharMay 19, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Has $2.55 Million Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)Jacobs Levy Equity Management Inc. reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 53.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 84,589 shares of the biopharmaceuticMay 18, 2025 | marketbeat.comNicholas Investment Partners LP Reduces Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)Nicholas Investment Partners LP trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 23.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 84,147 shares of the biopharmaceutical companyMay 16, 2025 | marketbeat.comJ. Goldman & Co LP Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)J. Goldman & Co LP cut its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 81.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,036 shares of the biopharmaceutical company's stock aftMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Purchases Shares of 150,000 TG Therapeutics, Inc. (NASDAQ:TGTX)Integral Health Asset Management LLC purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 150,000 shares of the biMay 14, 2025 | marketbeat.comBrevan Howard Capital Management LP Takes $453,000 Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Brevan Howard Capital Management LP bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 15,042 shares of the biopharmaceutical company's stock, valued at appMay 12, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Algert Global LLCAlgert Global LLC lessened its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 52.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 49,061 shares of the biopharmaceutical company's stock after selling 5May 12, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Northern Trust CorpNorthern Trust Corp lifted its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 8.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,532,929 shares of the biopharmaceutical company's stock after purchaMay 11, 2025 | marketbeat.comCantor Fitzgerald Predicts TG Therapeutics FY2025 EarningsTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of TG Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Cantor Fitzgerald analyst P. Agrawal now forecasts that the bioMay 10, 2025 | marketbeat.comQ3 Earnings Forecast for TG Therapeutics Issued By B. RileyTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at B. Riley upped their Q3 2025 earnings per share estimates for shares of TG Therapeutics in a research note issued to investors on Monday, May 5th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical companyMay 10, 2025 | marketbeat.comDecoding TG Therapeutics Inc (TGTX): A Strategic SWOT InsightMay 10, 2025 | gurufocus.comAnalysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), TG Therapeutics (TGTX) and Vertex Pharmaceuticals (VRTX)May 9, 2025 | theglobeandmail.comTG Therapeutics, Inc. (TGTX): Among the Best Cancer Stocks to Invest in for Long-Term GainMay 9, 2025 | insidermonkey.comB. Riley Brokers Lift Earnings Estimates for TG TherapeuticsTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities research analysts at B. Riley boosted their Q2 2025 earnings per share estimates for TG Therapeutics in a research report issued to clients and investors on Monday, May 5th. B. Riley analyst M. Mamtani now expects that the biopharmaceutMay 9, 2025 | marketbeat.comCornerstone Select Advisors LLC Buys Shares of 63,270 TG Therapeutics, Inc. (NASDAQ:TGTX)Cornerstone Select Advisors LLC purchased a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 63,270 shares of the biopharmaceutical company's stock, vaMay 9, 2025 | marketbeat.comLido Advisors LLC Takes $231,000 Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Lido Advisors LLC bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 7,680 shares of the biopharmaceutical company's stock, valued at approximately $231May 9, 2025 | marketbeat.comJ.P. Morgan Remains a Buy on TG Therapeutics (TGTX)May 8, 2025 | theglobeandmail.comFreestone Grove Partners LP Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Freestone Grove Partners LP acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 7,433 shares of the biopharMay 8, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Shares Gap Down - Here's What HappenedTG Therapeutics (NASDAQ:TGTX) Shares Gap Down - Should You Sell?May 7, 2025 | marketbeat.comTG Therapeutics Target of Unusually High Options Trading (NASDAQ:TGTX)TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) was the recipient of unusually large options trading on Monday. Investors acquired 8,465 call options on the company. This represents an increase of approximately 46% compared to the average volume of 5,801 call options.May 7, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Posts Earnings Results, Misses Expectations By $0.16 EPSTG Therapeutics (NASDAQ:TGTX - Get Free Report) announced its quarterly earnings data on Monday. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.May 7, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Buys Shares of 9,650 TG Therapeutics, Inc. (NASDAQ:TGTX)Susquehanna Fundamental Investments LLC purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,650 shareMay 7, 2025 | marketbeat.comTG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comTG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2025 Earnings Call TranscriptMay 6, 2025 | insidermonkey.comTG Therapeutics Boosts Retail Sentiment With Q1 Revenue Beat Even As Stock Tumbles On Profit Miss, Conservative OutlookMay 6, 2025 | msn.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD lifted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 264.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 297,101 shares of the biopharmaceutical company's stocMay 6, 2025 | marketbeat.comTG Therapeutics Inc (TGTX) Q1 2025 Earnings Call Highlights: Strong BRIUMVI Sales and Increased ...May 6, 2025 | gurufocus.comTG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the ShowMay 5, 2025 | benzinga.comWhy TG Therapeutics Stock Was Tumbling TodayMay 5, 2025 | fool.comTG Therapeutics: Share Price Slips On Q1 Earnings, Unsurprising Given ChallengesMay 5, 2025 | seekingalpha.comTG Therapeutics Shares Fall After 1Q Earnings MissMay 5, 2025 | marketwatch.comTG Therapeutics Stock Tumbles After Q1 Earnings Fall Short Of Wall Street Estimates: But Retail’s OptimisticMay 5, 2025 | msn.comTG Therapeutics stock sinks on profit missMay 5, 2025 | msn.comTG Therapeutics, Inc.: TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue GuidanceMay 5, 2025 | finanznachrichten.de Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address TGTX Media Mentions By Week TGTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TGTX News Sentiment▼1.540.87▲Average Medical News Sentiment TGTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TGTX Articles This Week▼108▲TGTX Articles Average Week Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Teva Pharmaceutical Industries News Summit Therapeutics News Intra-Cellular Therapies News Genmab A/S News Dr. Reddy's Laboratories News Moderna News Ascendis Pharma A/S News Viatris News Qiagen News Roivant Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TGTX) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.